表皮生长因子受体作为抗癌药物设计的靶点。

Epidermal growth factor receptor as a target for anti-cancer agent design.

机构信息

Department of Medicinal Chemistry, Shandong University, Jinan, PR China.

出版信息

Anticancer Agents Med Chem. 2010 Jul;10(6):491-503. doi: 10.2174/1871520611009060491.

DOI:10.2174/1871520611009060491

PMID:20698825

Abstract

The epidermal growth factor (EGF) receptors, one family of protein tyrosine kinases (PTK), are promising targets for the cancer therapy. Many potential inhibitors including monoclonal antibodies (mAbs), reversible inhibitors and irreversible inhibitors have been developed. Some of them have been approved by the FDA or in the stage of clinical trials. This report reviews the recent progress of the structures, functions and inhibitors of the epidermal growth factor receptor tyrosine kinases.

摘要

表皮生长因子（EGF）受体是蛋白酪氨酸激酶（PTK）家族的一个成员，是癌症治疗的有前途的靶点。已经开发出许多潜在的抑制剂，包括单克隆抗体（mAbs）、可逆抑制剂和不可逆抑制剂。其中一些已获得 FDA 批准或处于临床试验阶段。本报告综述了表皮生长因子受体酪氨酸激酶的结构、功能和抑制剂的最新进展。